Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Thursday 9 November 2017, 10:00 – 16:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present: 1. Prof Andrew Stevens, Chair Present for all notes
          2. Dr Andrea Manca Present for all notes
          3. Mr David Chandler Present for all notes
          4. Dr Derek Ward Present for all notes
          5. Mr John Hampson Present for all notes
          6. Dr Judith Wardle Present for all notes
          7. Mr Kamal Balakrishnan Present for all notes
          8. Prof Kathryn Abel Present for all notes
          9. Prof Matt Stevenson Present for all notes
         10. Dr Nigel Langford Present for all notes
         11. Dr Paul Tappenden Present for all notes
         12. Prof Peter Selby Present for all notes
         13. Dr Richard Nicholas Present for notes 1 to 16
         14. Prof Robert Walton Present for all notes
         15. Prof Stephen O'Brien Present for all notes

In attendance:

Ross Dent Technical Analyst, National Institute for Health and Care Excellence Present for notes 17 to 29

Sally Doss Technical Advisor, National Institute for Health and Care Excellence Present for notes 1 to 16

Alexandra Filby Technical Advisor, National Institute for Health and Care Excellence Present for notes 17 to 29

Tanith Musson Administrator, National Institute for Health and Care Excellence Present for all notes

Kirsty Pitt Technical Analyst, National Institute for Health and Clinical Excellence Present for notes 1 to 16
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of midostaurin for untreated acute myeloid leukaemia and tocilizumab for treating giant cell arteritis.

2. The Chair informed the Committee of the non-public observers at this meeting: Leslie Hayes, Dahlia Shalks and Sahar Sharif.

3. Apologies were received from Mr Michael Chambers, Dr Prithviraj Das, Ms Gail Coster and Prof Andrew Renehan.

Any other Business

4. None

Appraisal of midostaurin for untreated acute myeloid leukaemia [ID894]

Part 1 – Open session
5. The Chair welcomed the invited experts: Mike Dennis, Steven Knapper, Mousumi Biswas, and Nerys Woolacott to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Novartis to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

   7.1. Dr Andrea Manca, Mr David Chandler, Dr Derek Ward, Mr John Hampson, Dr Judith Wardle, Mr Kamal Balakrishnan, Prof Kathryn Abel, Prof Matt Stevenson, Dr Nigel Langford, Dr Paul Tappenden, Prof Peter Selby, Prof Robert Walton and Prof Stephen O’Brien, all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of midostaurin for untreated acute myeloid leukaemia

   7.2. Dr Richard Nicholas declared a non-financial, non-specific interest, stating that he wrote a paper with members of the Novartis economics team in Multiple Sclerosis published in 2017, which was unrelated to the treatment under consideration and for which he received no payment. 9.2.1 It was agreed that this declaration would not prevent Dr Richard Nicholas from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.

   8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of midostaurin for untreated acute myeloid leukaemia.

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

   9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of midostaurin for untreated acute myeloid leukaemia

10. The Chair introduced the lead team, Prof Stephen O’Brien, Mr David Chandler and Dr Derek Ward, who gave presentations on the clinical effectiveness and cost effectiveness of midostaurin for untreated acute myeloid leukaemia

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to
Meetings) Act 1960)” and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of midostaurin for untreated acute myeloid leukaemia

15.1. The committee decision was based on consensus.

16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

**Appraisal of tocilizumab for treating giant cell arteritis [ID1051]**

**Part 1 – Open session**

17. The Chair welcomed the invited experts: Justin Mason, Susan Mollan, Steve Palmer, Sahar Sharif and Nerys Woolacott to the meeting and they introduced themselves to the Committee.

18. The Chair welcomed company representatives from Roche to the meeting.

19. The Chair asked all Committee members to declare any relevant interests

19.1. Prof Andrew Stevens, Dr Andrea Manca, Mr David Chandler, Dr Derek Ward, Mr John Hampson, Dr Judith Wardle, Mr Kamal Balakrishnan, Prof Kathryn Abel, Prof Matt Stevenson, Dr Nigel Langford, Dr Paul Tappenden, Prof Peter Selby, Dr Richard Nicholas, Prof Robert Walton and Prof Stephen O’Brien all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of tocilizumab for treating giant cell arteritis

20. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

20.1. Susan Mollan declared a non-financial, non-specific interest, stating that she had previously participated on advisory boards for Roche

20.2. Kate Gilbert declared that she had attended a patient consultative meeting with Roche before clinical trials for this technology began.

21. The Chair asked all NICE Staff to declare any relevant interests.
21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of tocolizumab for treating giant cell arteritis

22. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

22.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of tocolizumab for treating giant cell arteritis

23. The Chair introduced the lead team, Mr Kamal Balakrishnan, Prof Peter Selby and Dr Judith Wardle, who gave presentations on the clinical effectiveness and cost effectiveness of tocolizumab for treating giant cell arteritis

24. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

25. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

26. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

27. Discussion on confidential information continued. This information was supplied by the company.

28. The Committee continued to discuss the clinical and cost effectiveness of tocolizumab for treating giant cell arteritis

28.1. The committee decision was based on consensus.

29. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

30. Tuesday 12 December, 10:00 – 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.